Abstract
Interventions to reduce the likelihood of relapse, or a return to substance abuse after a period of abstinence, are important components of substance abuse treatment. Treatment interventions for adolescence with substance use disorders should incorporate principles of relapse prevention. The relapse prevention model advanced by Marlatt and Gordon and others in the addiction field is a self-control model, based on a cognitive-behavioral approach. This model stands in contrast to a disease model, which many in the medical field have adhered to. This paper presents a summary of the key features of Marlatt and Gordons cognitive-behavioral approach to relapse prevention.
Keywords: Alcohol use disorders, treatment, substance use disorders, Interventions, relapse, abstinence, relapse prevention, addiction, self-control, cognitive-behavioral
Adolescent Psychiatry
Title: Relapse Prevention
Volume: 1 Issue: 2
Author(s): Richard Rosner
Affiliation:
Keywords: Alcohol use disorders, treatment, substance use disorders, Interventions, relapse, abstinence, relapse prevention, addiction, self-control, cognitive-behavioral
Abstract: Interventions to reduce the likelihood of relapse, or a return to substance abuse after a period of abstinence, are important components of substance abuse treatment. Treatment interventions for adolescence with substance use disorders should incorporate principles of relapse prevention. The relapse prevention model advanced by Marlatt and Gordon and others in the addiction field is a self-control model, based on a cognitive-behavioral approach. This model stands in contrast to a disease model, which many in the medical field have adhered to. This paper presents a summary of the key features of Marlatt and Gordons cognitive-behavioral approach to relapse prevention.
Export Options
About this article
Cite this article as:
Rosner Richard, Relapse Prevention, Adolescent Psychiatry 2011; 1 (2) . https://dx.doi.org/10.2174/2210676611101020131
DOI https://dx.doi.org/10.2174/2210676611101020131 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Users Perception of Risk and Benefits of Mood Modifying Drugs
Current Clinical Pharmacology Excitability of Dopamine Neurons: Modulation and Physiological Consequences
CNS & Neurological Disorders - Drug Targets Structural Comparison of p38 Inhibitor-Protein Complexes: A Review of Recent p38 Inhibitors Having Unique Binding Interactions
Current Topics in Medicinal Chemistry Commentary [ Research Highlights(To miR or Not to miR: That is the Question in ALS Disease ]
CNS & Neurological Disorders - Drug Targets Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder
Current Medicinal Chemistry Development and Optimization by Quality by Design Strategies of Frovatriptan Orally Disintegrating Tablets for Migraine Management
Current Drug Delivery Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research Effects of Mindfulness on Diabetes Mellitus: Rationale and Overview
Current Diabetes Reviews Editorial (Hot Topic: Epidemiology & Risk Factors for Alzheimer’s Disease)
Current Alzheimer Research Cerebrovascular Profile Assessment in Parkinson's Disease Patients
CNS & Neurological Disorders - Drug Targets Attention Deficit Hyperactivity Disorder and N-methyl-D-aspartate (NMDA) Dysregulation
Current Pharmaceutical Design Brain Peptides for the Treatment of Neuropsychiatric Disorders
Current Pharmaceutical Design Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems
Current Neuropharmacology What is Tobacco Smoke? Sociocultural Dimensions of the Association with Cardiovascular Risk
Current Pharmaceutical Design Leptin, Immune Responses and Autoimmune Disease. Perspectives on the Use of Leptin Antagonists
Current Pharmaceutical Design Cell-Based Therapy to Promote Angiogenesis in the Brain Following Ischemic Damage
Current Vascular Pharmacology Molecular Mechanisms Involved in the Aging of the T-cell Immune Response
Current Genomics Potential Targets for the Development of Novel Antidepressants: Future Perspectives
CNS & Neurological Disorders - Drug Targets Editorial: Pain in Dementia: A Distressing Combination of Several Factors
Current Alzheimer Research Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery